Full-Time

Scientist I

Translational Sciences

Posted on 10/18/2024

Tr1X

Tr1X

11-50 employees

Develops cellular immunotherapies for autoimmune diseases

Compensation Overview

$120k - $135kAnnually

Mid, Senior

No H1B Sponsorship

San Diego, CA, USA

Category
Bioinformatics
Public Health
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • MS + 4 years of industry experience, or PhD with experience in immunology, cell biology, or related fields, and conducting bioanalytical assay development.
  • At least 2 years of experience in a translational/biomarker setting.
  • Extensive experience in cell-based assays to characterize T cells, using immunological techniques such as flow cytometry, multi-plexed immunoassays (e.g., MSD, ELISA), and molecular techniques (e.g., RNAseq, Nanostring, dPCR), ideally supporting clinical trial sample analysis.
  • Strong ability to critically analyze data, optimize assays independently, and collaborate effectively within a team, with excellent verbal and written communication skills.
  • Impeccable documentation skills, including timely electronic lab notebook entries.
  • Strong attention to detail to detect experimental anomalies and artifacts.
  • Ability to write technical documents such as SOPs and qualification reports, and adhere to SOP specifications without deviation.
  • Ability to work under tight deadlines, manage multiple tasks, and drive them to completion.
  • The disposition to thrive in a fast-paced startup environment with an agile and organized mindset.
  • To be able to safely conduct experiments while wearing required PPE.
Responsibilities
  • Develop cell-based and molecular bioanalytical methods to interrogate biomarkers of diseases and responses to therapy.
  • Execute clinical sample processing and report reproducible results.
  • Analyze large amount of data real-time and present findings at team/departmental meetings.
  • Evaluate various protocols and methodologies in support of clinical studies.
  • Collaborate to ensure seamless transfer of assays and knowledge between teams and personnel.
  • Contribute to the development of biomarker and translational strategies.
  • Maintain detailed and highly organized documentation of experimental procedures.
Desired Qualifications
  • Prior experience with assay qualification and/or validation.
  • Knowledge of GxP / Quality systems / Compliance Framework for translational activities.
  • Prior experience working with partner labs/CROs and transferring assays.

Tr1X focuses on developing cellular immunotherapies aimed at treating autoimmune and inflammatory diseases. The company uses a proprietary platform to create cell therapy products that help rebalance the immune system and restore its natural balance, which is essential for long-term health. Unlike many competitors, Tr1X specializes in first-in-class therapies that target the underlying causes of immune system dysfunction rather than just alleviating symptoms. The goal of Tr1X is to provide advanced therapeutic solutions that lead to lasting tolerance in patients, improving their quality of life.

Company Size

11-50

Company Stage

Series A

Total Funding

$73M

Headquarters

San Diego, California

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance for TRX103 IND boosts Tr1X's credibility and market potential.
  • $75M Series A funding supports rapid development of Tr1X's therapies.
  • Growing autoimmune therapeutics market offers significant opportunities for Tr1X's products.

What critics are saying

  • Emerging competition in allogeneic Treg therapy could impact Tr1X's market share.
  • High manufacturing costs may pose financial risks for Tr1X.
  • Regulatory hurdles could delay Tr1X's product development and market entry.

What makes Tr1X unique

  • Tr1X uses a proprietary platform for novel cellular immunotherapies.
  • The company focuses on allogeneic regulatory T-cell therapies for autoimmune diseases.
  • Tr1X's TRX103 is the first allogeneic engineered Tr1 regulatory T cell product.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

401(k) Company Match

Flexible Work Hours

Stock Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Apr 10th, 2024
Tr1X Announces Fda Clearance Of First Investigational New Drug Application For Trx103, An Allogeneic Regulatory T-Cell Therapy To Treat Autoimmune Diseases

Company to initiate Phase 1 study of Graft versus Host Disease (GvHD) prevention in patients undergoing hematopoietic stem cell transplantation in Q2 2024Second IND application for refractory Crohn's disease expected in Q3 2024Highly scalable platform enables efficient pipeline expansion and opportunity beyond first two indicationsSAN DIEGO, April 10, 2024 /PRNewswire/ -- Tr1X, Inc., an autoimmune and inflammatory disease cell therapy company focused on the development of novel allogeneic regulatory T cell therapies (Allo-Tregs) and allogeneic regulatory T cells expressing Chimeric Antigen Receptors (Allo-CAR Tregs), today announced the U.S. Food and Drug Administration (FDA) accepted the company's Investigational New Drug (IND) application for TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched hematopoietic stem cell transplantation (HSCT). The company plans to initiate a Phase 1 study of TRX103, an investigational allogeneic off-the-shelf Tr1 Treg therapy, for this indication in the second quarter of 2024. Additionally, the company is on track to submit an IND for TRX103 for patients with refractory Crohn's disease in the third quarter of 2024."The FDA's clearance of our IND for TRX103, the first ever allogeneic engineered Tr1 regulatory T cell product, is an important milestone that could quickly provide us with proof-of-concept data while we continue to develop TRX103 for multiple autoimmune and inflammatory diseases, including Crohn's disease," said Maria Grazia Roncarolo M.D., Co-Founder, President and Head of R&D at Tr1X. "Donor-derived autologous Tr1 cells have shown clinical promise in improving immune reconstitution and reducing GvHD but have limited potential due to lack of feasibility and high cost. TRX103, an off-the-shelf product with unique biological properties compared to other Treg and CAR-T cell therapies, has the potential to reduce inflammation, suppress pathogenic cells, and reset the immune system

BioSpace
Jan 18th, 2024
Cell Therapy Startup Tr1X Emerges from Stealth with $75M Series A

Cell therapy startup Tr1X emerges from stealth with $75M Series A.

PR Newswire
Jan 17th, 2024
Tr1X, Inc. Announces $75 Million Series A Financing to Develop Best-in-Class Universal Allogeneic Regulatory T (Treg) and CAR-Treg Cell Therapies to Treat and Potentially Cure Autoimmune and Inflammatory Diseases

Financing led by The Column Group, with participation from NEVA SGR and Alexandria Ventures, will enable immediate and expedited execution to advance Tr1X's...

INACTIVE